JP2015504921A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504921A5 JP2015504921A5 JP2014554868A JP2014554868A JP2015504921A5 JP 2015504921 A5 JP2015504921 A5 JP 2015504921A5 JP 2014554868 A JP2014554868 A JP 2014554868A JP 2014554868 A JP2014554868 A JP 2014554868A JP 2015504921 A5 JP2015504921 A5 JP 2015504921A5
- Authority
- JP
- Japan
- Prior art keywords
- hetre
- use according
- medicament
- microbial infection
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002253 acid Substances 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- IUKXMNDGTWTNTP-OAHXIXLCSA-N 15(S)-HETrE Chemical compound CCCCC[C@H](O)\C=C\C=C/C\C=C/CCCCCCC(O)=O IUKXMNDGTWTNTP-OAHXIXLCSA-N 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 8
- 208000015181 infectious disease Diseases 0.000 claims 5
- 230000000813 microbial effect Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010052428 Wound Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 229960000282 metronidazole Drugs 0.000 claims 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000037390 scarring Effects 0.000 claims 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 claims 1
- 244000303769 Amaranthus cruentus Species 0.000 claims 1
- 108010001478 Bacitracin Proteins 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 241000069665 Crenosoma striatum Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000495778 Escherichia faecalis Species 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 108010015899 Glycopeptides Proteins 0.000 claims 1
- 102000002068 Glycopeptides Human genes 0.000 claims 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 229930193140 Neomycin Natural products 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- 108010093965 Polymyxin B Proteins 0.000 claims 1
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 229960003022 amoxicillin Drugs 0.000 claims 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims 1
- 229960000723 ampicillin Drugs 0.000 claims 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims 1
- 229960000603 cefalotin Drugs 0.000 claims 1
- 229960004261 cefotaxime Drugs 0.000 claims 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 claims 1
- 229960000484 ceftazidime Drugs 0.000 claims 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims 1
- 229960001668 cefuroxime Drugs 0.000 claims 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims 1
- 229940106164 cephalexin Drugs 0.000 claims 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 229940047766 co-trimoxazole Drugs 0.000 claims 1
- 229960003722 doxycycline Drugs 0.000 claims 1
- 229940124307 fluoroquinolone Drugs 0.000 claims 1
- -1 fluoroquinolone Chemical compound 0.000 claims 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical group N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 229960002182 imipenem Drugs 0.000 claims 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims 1
- 229960003376 levofloxacin Drugs 0.000 claims 1
- 229960002260 meropenem Drugs 0.000 claims 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims 1
- 229960004927 neomycin Drugs 0.000 claims 1
- 229940053050 neomycin sulfate Drugs 0.000 claims 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- 229920000024 polymyxin B Polymers 0.000 claims 1
- 229960005266 polymyxin b Drugs 0.000 claims 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 1
- 229960002180 tetracycline Drugs 0.000 claims 1
- 229930101283 tetracycline Natural products 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960000707 tobramycin Drugs 0.000 claims 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 1
- 229960003500 triclosan Drugs 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- UCRLQOPRDMGYOA-DFTDUNEMSA-L zinc;(4r)-4-[[(2s)-2-[[(4r)-2-[(1s,2s)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2s,3s)-1-[[(3s,6r,9s,12r,15s,18r,21s)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2s)-butan-2-yl]-6-(carbox Chemical compound [Zn+2].C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC([O-])=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@H](CC([O-])=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 UCRLQOPRDMGYOA-DFTDUNEMSA-L 0.000 claims 1
- WLKCSMCLEKGITB-XWJJKCKWSA-N 15-HEPE Chemical compound CC\C=C/CC(O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-XWJJKCKWSA-N 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261591036P | 2012-01-26 | 2012-01-26 | |
| US61/591,036 | 2012-01-26 | ||
| US13/478,990 | 2012-05-23 | ||
| US13/478,990 US20120264705A1 (en) | 2012-01-26 | 2012-05-23 | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| PCT/US2013/023201 WO2013112876A1 (en) | 2012-01-26 | 2013-01-25 | Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017217054A Division JP2018065818A (ja) | 2012-01-26 | 2017-11-10 | Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む抗菌組成物およびそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015504921A JP2015504921A (ja) | 2015-02-16 |
| JP2015504921A5 true JP2015504921A5 (https=) | 2016-03-10 |
| JP6557009B2 JP6557009B2 (ja) | 2019-08-07 |
Family
ID=47006834
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014554868A Expired - Fee Related JP6557009B2 (ja) | 2012-01-26 | 2013-01-25 | Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む抗菌組成物およびそれらの使用方法 |
| JP2017217054A Pending JP2018065818A (ja) | 2012-01-26 | 2017-11-10 | Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む抗菌組成物およびそれらの使用方法 |
| JP2019176350A Pending JP2020023513A (ja) | 2012-01-26 | 2019-09-27 | Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む抗菌組成物およびそれらの使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017217054A Pending JP2018065818A (ja) | 2012-01-26 | 2017-11-10 | Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む抗菌組成物およびそれらの使用方法 |
| JP2019176350A Pending JP2020023513A (ja) | 2012-01-26 | 2019-09-27 | Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む抗菌組成物およびそれらの使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20120264705A1 (https=) |
| EP (1) | EP2806868A4 (https=) |
| JP (3) | JP6557009B2 (https=) |
| KR (1) | KR20140117379A (https=) |
| CN (1) | CN104114166A (https=) |
| AU (1) | AU2013211982A1 (https=) |
| BR (1) | BR112014018421A8 (https=) |
| CA (1) | CA2857046A1 (https=) |
| HK (1) | HK1198921A1 (https=) |
| IL (1) | IL232777A0 (https=) |
| MX (1) | MX2014006947A (https=) |
| PH (1) | PH12014501693A1 (https=) |
| RU (1) | RU2014134720A (https=) |
| SG (1) | SG11201404088TA (https=) |
| WO (1) | WO2013112876A1 (https=) |
| ZA (1) | ZA201403948B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| RU2014119948A (ru) * | 2011-10-19 | 2015-11-27 | Дигнити Сайенсиз Лимитед | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| US8293790B2 (en) * | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| US9855236B2 (en) | 2011-10-19 | 2018-01-02 | Ds Biopharma Limited | Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof |
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| GB201307082D0 (en) * | 2013-04-19 | 2013-05-29 | Dignity Sciences Ltd | Pharmaceutical composition comprising 15-HETrE and methods of using the same |
| WO2015042442A1 (en) * | 2013-09-19 | 2015-03-26 | Dignity Sciences Limited | Pharmaceutical compositions comprising dha, epa, and/or gla and an antibiotic agent and methods of use thereof |
| JP2016538288A (ja) | 2013-11-15 | 2016-12-08 | ディグニティ サイエンシス リミテッド | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
| EP3091959A4 (en) * | 2014-01-10 | 2017-09-20 | Dignity Sciences Limited | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |
| US9682055B2 (en) | 2014-06-04 | 2017-06-20 | Dignity Sciences Limted | Pharmaceutical compositions comprising DGLA and use of same |
| LT6177B (lt) | 2014-10-10 | 2015-07-27 | Uab "Biocentras" | Fermentų kompleksų išskyrimas iš steptomyces gougerotii 101, daugiafermentinių biopreparatų ruošimas bei taikymas |
| MA41120A (fr) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| US20180008567A1 (en) * | 2015-01-16 | 2018-01-11 | Afimmune Limited | Compositions comprising 15-hepe and methods of using the same |
| ES2851525T3 (es) | 2015-07-21 | 2021-09-07 | Afimmune Ltd | Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia |
| CA3129008A1 (en) | 2015-12-18 | 2017-06-22 | Afimmune Limited | Compositions comprising 15-hepe and methods of using the same |
| US20200206173A1 (en) | 2017-08-30 | 2020-07-02 | Conopco, Inc., D/B/A Unilever | A personal care composition |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4344930A (en) * | 1975-10-30 | 1982-08-17 | Colgate-Palmolive Company | Skin care sponge |
| JP4926310B2 (ja) * | 1996-02-15 | 2012-05-09 | エルテーベー４・スウェーデン・アクチェボラーグ | 抗ウイルス薬および抗腫瘍薬としてのロイコトリエンｂ４またはその類似体の使用 |
| US5789441A (en) * | 1996-02-15 | 1998-08-04 | Virocell Inc. | Leukotriene B4 as an antiviral and anti-neoplastic agent |
| US6190645B1 (en) * | 1999-07-15 | 2001-02-20 | Playtex Products, Inc. | Sunscreen for the scalp hair and hair |
| US20030073930A1 (en) * | 2001-10-17 | 2003-04-17 | Morrissey Gerald R. | Methods and device for preventing or healing injured nipples or areolas in mammalian females or for obtaining samples from nipples in mammalian females |
| US20030105445A1 (en) * | 2001-11-30 | 2003-06-05 | Kimberly-Clark Worldwide, Inc. | Breast pad assembly containing a skin benefit ingredient |
| WO2005102309A2 (en) * | 2004-04-26 | 2005-11-03 | Ltb4 Sweden Ab | In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration |
| CA2674210A1 (en) * | 2005-12-30 | 2007-07-12 | Intradigm Corporation | Sirna compositions promoting scar-free wound healing of skin and methods for wound treatment |
| CA2670158A1 (en) * | 2006-11-23 | 2008-05-29 | Cargill, Incorporated | Natural equivalent of chemically modified starch |
| CN101715349B (zh) * | 2007-05-08 | 2012-07-18 | 美国Rq生物科技有限公司 | 治疗革兰氏阴性细菌感染的治疗组合物及方法 |
| EP2159732A1 (en) * | 2008-08-21 | 2010-03-03 | Thomson Licensing | Method and device for code obfuscation |
| GB0907413D0 (en) * | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| US8637298B2 (en) * | 2009-06-16 | 2014-01-28 | E I Du Pont De Nemours And Company | Optimized strains of yarrowia lipolytica for high eicosapentaenoic acid production |
| US8293790B2 (en) * | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
-
2012
- 2012-05-23 US US13/478,990 patent/US20120264705A1/en not_active Abandoned
-
2013
- 2013-01-25 SG SG11201404088TA patent/SG11201404088TA/en unknown
- 2013-01-25 CA CA2857046A patent/CA2857046A1/en not_active Abandoned
- 2013-01-25 EP EP13741302.7A patent/EP2806868A4/en not_active Withdrawn
- 2013-01-25 KR KR1020147018192A patent/KR20140117379A/ko not_active Abandoned
- 2013-01-25 JP JP2014554868A patent/JP6557009B2/ja not_active Expired - Fee Related
- 2013-01-25 MX MX2014006947A patent/MX2014006947A/es unknown
- 2013-01-25 WO PCT/US2013/023201 patent/WO2013112876A1/en not_active Ceased
- 2013-01-25 RU RU2014134720A patent/RU2014134720A/ru not_active Application Discontinuation
- 2013-01-25 HK HK14112445.0A patent/HK1198921A1/xx unknown
- 2013-01-25 BR BR112014018421A patent/BR112014018421A8/pt not_active Application Discontinuation
- 2013-01-25 CN CN201380006224.7A patent/CN104114166A/zh active Pending
- 2013-01-25 AU AU2013211982A patent/AU2013211982A1/en not_active Abandoned
-
2014
- 2014-02-21 US US14/186,200 patent/US20140171358A1/en not_active Abandoned
- 2014-05-25 IL IL232777A patent/IL232777A0/en unknown
- 2014-05-29 ZA ZA2014/03948A patent/ZA201403948B/en unknown
- 2014-07-25 PH PH12014501693A patent/PH12014501693A1/en unknown
-
2017
- 2017-11-10 JP JP2017217054A patent/JP2018065818A/ja active Pending
-
2019
- 2019-09-27 JP JP2019176350A patent/JP2020023513A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504921A5 (https=) | ||
| RU2014134720A (ru) | Противомикробные композиции, содержащие dgla, 15-онера и/или 15-hetre, и способы их применения | |
| SA520411571B1 (ar) | مركبات كرومان مونوباكتام لعلاج العدوى البكتيرية | |
| CN101573031A (zh) | 抗微生物组合物 | |
| JP2012522037A5 (https=) | ||
| WO2010007381A1 (en) | Antibacterial combination therapy for the treatment of gram positive bacterial infections | |
| WO2012017349A3 (en) | Topical pharmaceutical composition comprising nanonized silver sulfadiazine and chlorhexidine gluconate | |
| JP2016507547A5 (https=) | ||
| RU2015132369A (ru) | Комбинированная терапия для лечения нозокомиальной пневмонии | |
| FI3006038T3 (fi) | Oritavansiinin yksittäisannokset bakteeri-infektion hoitoon tai ehkäisyyn | |
| Gunjan et al. | A comparative study of the effect of different topical agents on burn wound infections | |
| WO2020028561A1 (en) | Bismuth-thiol compositions and methods for treating wounds | |
| JP2018500387A5 (https=) | ||
| MX2023011616A (es) | Compuestos de lactivicina, su preparacion y uso como agentes antibacterianos. | |
| JP2008520660A5 (https=) | ||
| NZ706734A (en) | Pharmaceutical compositions useful for the treatment or control of bacterial infections | |
| JP2024009968A5 (https=) | ||
| JP5276653B2 (ja) | カルバペネム類を含む殺菌性抗ｍｒｓａ活性医薬組成物 | |
| JP6525999B2 (ja) | 抗菌性組成物 | |
| JP2016510749A5 (https=) | ||
| Alexpandi et al. | Proteomic insights into the multi-target mechanism and therapeutic application of citronellol-loaded carboxymethyl chitosan-based hydrogel for wound infection treatment | |
| CN106794250A (zh) | 包含抗菌剂的药物组合物 | |
| JP2015524461A5 (https=) | ||
| JP2016538262A (ja) | 抗菌剤を含む医薬品組成物 | |
| WO2009124086A3 (en) | Antibacterial drug for treatment of staphylococcus aureus and other gram-positive bacterial infections |